共 100 条
- [1] Zhong N(2007)Prevalence of chronic obstructive pulmonary disease in China: a large, population-based survey Am. J. Respir. Crit. Care Med. 176 753-760
- [2] Wang C(2018)Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study Lancet 391 1706-1717
- [3] Rogliani P(2019)Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease Expert Opin. Pharmacother. 20 737-750
- [4] Salpeter SR(2004)Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis Chest 125 2309-2321
- [5] Ormiston TM(2008)Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis Jama 300 1439-1450
- [6] Salpeter EE(2013)Inhaled corticosteroids in COPD and the risk of serious pneumonia Thorax 68 1029-1036
- [7] Singh S(2007)Mucolytics, expectorants, and mucokinetic medications Respir. Care 52 859-865
- [8] Loke YK(2012)Effects of comprehensive therapy based on traditional Chinese medicine patterns in stable chronic obstructive pulmonary disease: a four-center, open-label, randomized, controlled study BMC Complement. Altern. Med. 12 197-2488
- [9] Furberg CD(2016)Randomized, double-blind, placebo-controlled superiority trial of the Yiqigubiao pill for the treatment of patients with chronic obstructive pulmonary disease at a stable stage Exp. Ther. Med. 12 2477-733
- [10] Suissa S(2015)Systems pharmacology-based dissection of mechanisms of Chinese medicinal formula Bufei Yishen as an effective treatment for chronic obstructive pulmonary disease Sci. Rep. 5 9146378-86